Reversing the effects of Alzheimer's Disease: Dr. Ron Geyer on NeuroEPO
Release Date: 02/19/2023
In the Trenches: Dr. James Stempien on Emergency Medicine
Researchers Under the Scope
James Stempien (MD) has navigated some of the most challenging corners of emergency medicine, from the frigid isolation of Inuvik to the bustling corridors of Saskatoon’s emergency departments. His experience in low-tech outposts has shaped his approach to modern emergency care. “When things aren’t going well you see it in the emergency department first,” Stempien said. “We’re the front door. We’re always open.” As provincial department head of emergency medicine, Stempien sees patients on their worst days in hospitals bursting at the seams, struggling to...
info_outline
All’s Not Lost: A Roadmap to Treating Hepatitis C on the Prairies
Researchers Under the Scope
As the world aims to eradicate hepatitis C (HCV) by 2030, Carrielynn Lund and Dr. Alexandra King’s team created a how-to guide. is a step-by-step guide to tackling a spike of new infections across the three Canadian prairie provinces. Hepatitis C (HCV) causes severe liver disease, and was notoriously difficult to treat until the introduction of direct-acting antivirals a decade ago — antivirals which boast a remarkable 95% success rate. Despite this advancement, Lund and Dr. King say Saskatchewan, Alberta and Manitoba need to know why HCV cases keep rising, particularly in...
info_outline
Exercise Your Right to Breathe: Dr. Brianne Philipenko & Asthma
Researchers Under the Scope
Brianne Philipenko (MD) was midway through her respirology fellowship in Calgary when the Covid-19 pandemic shut down the city. She started interval workouts at home using Nike’s fitness app — when inspiration struck. “Coming up with a creative, innovative way to allow people to access an exercise program outside of the typical organized pulmonary rehabilitation in a gym setting was something that I became really interested in,” said Philipenko.. As a respirologist, Philipenko was already frustrated by the lack of ‘mainstay’ guidelines on incorporating exercise...
info_outline
Dr. Sarah Forgie: Why the New Dean of Medicine Taught Herself the Ukelele
Researchers Under the Scope
In this episode, we gain insight into Dr. Sarah Forgie, the new Dean of the College of Medicine. She discusses her innovative teaching methods, her career as a pediatric infectious disease specialist, and her vision for advancing Saskatchewan’s College of Medicine. Dr. Forgie also shares the story behind her decision to learn the ukulele. Born to family physicians, Dr. Forgie grew up in Lynn Lake, Manitoba, a remote fly-in mining community. Her family later relocated to Winnipeg, where Dr. Forgie credits much of her motivation to her mother, who encouraged her to pursue both medicine and...
info_outline
Grey Area: Dr. John Howland on Cannabis & Budding Brains
Researchers Under the Scope
A behavioural neuroscientist in Saskatoon is uncovering marijuana’s effects on fetal brain development. After recently winning a five-year CIHR grant of $960,076 in the spring of 2024, Dr. John Howland’s lab at the University of Saskatchewan is expanding its work examining prenatal exposure to cannabis smoke. Howland’s teams will assess the way cannabis exposure alters higher brain functions like memory and learning in both rats and mice. Compared to cannabis injections in the past, the professor of Anatomy, Physiology and Pharmacology at the College of Medicine said exposing...
info_outline
Innovating and Bridging Gaps in IBD Care: Dr. Juan-Nicolás Peňa-Sánchez
Researchers Under the Scope
Growing up in Columbia had a profound impact on Dr. Juan-Nicolas Pẽna-Sànchez. In this episode, hear why the former family physician pivoted, becoming Saskatchewan's lead in finding the best ways to treat Crohn's disease and ulcerative colitis in rural and Indigenous patients. Even as a teenager, Juan-Nicolás Peña-Sánchez could see stark differences in health for those who had medical coverage — and those without, thanks to his stepfather, an emergency department physician. “I used to go with him sometimes on shifts to learn and shadow him,” said Peña-Sánchez said. “The...
info_outline
Cuts Like a NanoKnife: Dr. Mike Moser
Researchers Under the Scope
"When I got into medical school, the last thing in the world I wanted to be was a surgeon because I couldn't stand the sight of blood," said Dr. Mike Moser. Fast-forward to the present day, where Moser is now one of Saskatchewan's top kidney transplant surgeons, winning last year's Golden Scalpel Award for Pre-clerkship Education, the 2022 Logan Boulet Humanitarian of the Year Award, and numerous teaching awards. In this episode, the professor of general surgery at the University of Saskatchewan's College of Medicine takes us back to one pivotal day where everything changed, propelling...
info_outline
Walking the Talk: Dr. Daniel Fuller on Urban Health and Mobility
Researchers Under the Scope
As an undergrad, Daniel Fuller didn’t have a car, nor was he keen on taking the bus. “I rode my bike to university every day in the fall and then just kept on going and never stopped,” said Fuller, a former national and international canoe/kayak athlete. As he pedaled, Fuller watched the way people used trails, sidewalks and roads. “I really started to get into active transportation, how people move around cities and how we can get people active -- outside of the sport environment,” said Fuller, now an associate professor in Community Health and...
info_outline
Anatomy of Success: Three Researchers, Three Grants, One Goal
Researchers Under the Scope
From the laboratory to saving lives, this episode brings together three outstanding researchers from the University of Saskatchewan’s Department of Anatomy, Physiology, and Pharmacology (APP) as they discuss their work and its implications for cardiac care. Dr. Michelle Collins, Dr. Scott Widenmaier, and Dr. Changting Xiao are all recent recipients of research grants from Heart & Stroke (formerly the Heart and Stroke Foundation of Canada). In Canada, one per cent of newborns have congenital heart defects. Thanks to advances in cardiac care, up to 85 per cent of these...
info_outline
Dr. Jacob Alhassan and the Politics of Expendability
Researchers Under the Scope
"Pushing politicians to do what is good for the health of the people, there's no way around it," said Dr Jacob Alhassan. Born and raised in a rural Ghanaian village, Alhassan grew up without electricty and paved roads. He watched women die in childbirth. He grew resentful of health systems that left the poorest people to fend for themselves, while the rich thrived. Alhassan decided to take action. At first, he thought he would study hard to become a local hospital administrator. Partway through his university years, Alhassan began to dream even bigger. In this episode, he looks back at his...
info_outlineFor decades, families have watched Alzheimer's disease steal their loved ones' cognitive function. It's the most common form of dementia; one that affects a third of people over the age of 85.
It's a disease Dr. Ron Geyer and Dr. Andrew Kirk want to tackle.
Right now, most pharmaceuticals target the symptoms of Alzheimer's disease, without addressing its root cause. Most lose their effectiveness after three months.
Geyer, a biochemist and professor of pathology at the University of Saskatchewan's College of Medicine, said a novel protein could change that.
"They did a first clinical trial with this drug and they showed pretty exceptional efficacy," said Geyer.
NeuroEPO, first developed by researchers at the Center for Molecular Immunology in Cuba, stimulates red blood cells in the brain. It's a recombinant form of the naturally produced erythropoietin protein (EPO), which stops neuron cells from dying, promoting their growth and communication mechanisms.
During its first round of human trials in early-stage Alzheimer's disease patients, 82 per cent of those receiving the treatment saw stabilization in their cognitive function. For more than half receiving the drug, cognitive function improved.
Alzheimer's disease progressed and worsened for almost everyone receiving the placebo.
"We decided to move this forward and do a Phase Two trial in Canada," Geyer said.
Once the study is approved by Health Canada, trials will involve between 80 and 100 patients. Geyer said so far, everything is on track to begin testing NeuroEPO this summer.
The trick, he said, is delivering the drug directly to the brain.
"It breaks down in the blood quicker than normal EPO, so that's good in that it doesn't cause side effects," Geyer said.
He said his research group has teamed up with Rocket Science Health Inc., a company that's developed a way to deliver NeuroEPO through the nose to the brain.
Compared to a Covid-19 nasal swab, Geyer said the delivery mechanism for this drug is 'much more comfortable'.
Working with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, Geyer said his team is also expanding PET scans and neurological diagnostic tools for patients taking part in the study.
"We're hoping that with that, with those diagnostic assays, including MRI to measure the total brain volume, that the clinicians can use this information immediately as the trial starts to better diagnose their Alzheimer's patients, provide more clarity on the diagnosis, let them develop a treatment plan earlier."
Geyer said patients and doctors in Saskatchewan have already contacted his team, trying to sign up.
"We want to make it as broadly available as possible," he said.
Still, NeuroEPO will not be widely available, until a third-phase trial in the future which proves the drug's efficacy, shows no adverse effects, and involves at least 300-500 patients with Alzheimer's disease.
Geyer said his team is up to the challenge.
"It's almost impossible to find someone who doesn't know someone who has some form of dementia," said Geyer. "The ultimate goal is to keep people out of the hospital."